Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Intuitive Surgical (ISRG) Q2 Earnings Miss, Procedures Recover
12:53pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Intuitive Surgical's (ISRG) second-quarter results reflect health demand for procedures despite the resurgence of COVID-19 infections.
Here's Why Glaukos (GKOS) is a Great Momentum Stock to Buy
04:00pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Does Glaukos (GKOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?
02:30pm, Monday, 18'th Jul 2022 Zacks Investment Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Here's Why You Should Add Glaukos (GKOS) to Your Portfolio
11:32am, Wednesday, 13'th Jul 2022
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Best Momentum Stocks to Buy for July 13th
11:32am, Wednesday, 13'th Jul 2022
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
New Strong Buy Stocks for July 13th
08:29am, Wednesday, 13'th Jul 2022
KMI, UFCS, GKOS, SPPI and BECN have been added to the Zacks Rank #1 (Strong Buy) List on July 13, 2022.
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
07:00am, Wednesday, 13'th Jul 2022
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
03:09pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
12:48pm, Wednesday, 08'th Jun 2022
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
10:20am, Thursday, 02'nd Jun 2022 Zacks Investment Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
10:20am, Wednesday, 11'th May 2022 Zacks Investment Research
Sector ETF report for XHE
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
03:04pm, Tuesday, 10'th May 2022 Zacks Investment Research
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
12:48pm, Tuesday, 10'th May 2022
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
10:45pm, Wednesday, 04'th May 2022 Zacks Investment Research
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
08:18pm, Wednesday, 04'th May 2022
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
